Engitix raises €48.6M Series A round
19 January 2022· London, United Kingdom· health, biotech, oncology, fibrosis, drug_discovery, ai, b2b
To boost its drug discovery pipeline in fibrosis and cancer, expand its team, facilities, and operations, and advance preclinical programs through candidate selection and IND-enabling studies. The funding also supports a strategic collaboration with Dompé to identify new treatments for fibrosis and liver-associated solid tumors.
Investors
LeadNetherton Investments
Also participating
Dompé farmaceutici S.P.A.
About Engitix
Stage
Series A
Headquarters
London, United Kingdom
Founded
2016
Team Size
51–200
Sectors
healthbiotechoncologyfibrosisdrug_discoveryaib2b